Raymond James initiates QXO stock with Outperform rating on acquisition strategy
XBiotech Inc. (NASDAQ:XBIT) announced the results of its annual meeting of shareholders held Friday. According to a press release statement based on the company’s filing with the Securities and Exchange Commission, shareholders voted in favor of all proposals recommended by the board of directors.
Shareholders elected five directors to the board: John Simard, Thomas Kündig, Craig Rademaker, Tevi D. Troy, and David Soffer. The votes in favor for each nominee ranged from 12,301,285 to 12,698,614, with abstentions between 166,518 and 563,847. There were 2,824,207 broker non-votes for each nominee.
The appointment of Whitley Penn LLP as XBiotech’s independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. The vote tally was 15,206,712 in favor, 413,673 against, and 68,954 abstentions, with no broker non-votes recorded.
Shareholders also approved, on an advisory basis, the compensation of the company’s named executive officers, with 11,336,500 votes in favor, 1,460,498 against, and 68,134 abstentions. There were 2,824,207 broker non-votes on this proposal.
In addition, the company’s 2025 Equity Incentive Plan received approval, with 11,952,280 votes in favor, 904,108 against, and 8,744 abstentions. Broker non-votes for this item totaled 2,824,207.
All matters presented at the annual meeting, including the election of directors, ratification of the auditor, advisory vote on executive compensation, and the equity plan, were approved as recommended by XBiotech’s board. The information in this article is based on a press release statement and the company’s SEC filing.
In other recent news, XBiotech Inc . announced the appointment of Dr. Thomas Kündig and Craig Rademaker to its board of directors. Dr. Kündig will also serve on the Compensation Committee, while Mr. Rademaker will join the Audit Committee. Their appointments are effective immediately and will last until the company’s 2025 Annual General Meeting. Dr. Kündig is noted for his extensive experience in clinical care, research, and leadership, particularly in immunodermatology and cancer immunotherapy. He holds positions as the Director of the Department of Dermatology at the University Hospital Zurich and as a Full Professor at the University of Zurich. Additionally, Dr. Kündig has held previous board roles with the Swiss Society for Dermatology & Venereology and the European Dermatology Forum. This move is part of XBiotech’s ongoing efforts to strengthen its board with experienced professionals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.